Literature DB >> 24343663

DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins.

Lucas Ferrari de Andrade1, Mark J Smyth2, Ludovic Martinet3.   

Abstract

Natural killer (NK) cells represent key innate immune cells that restrain viral infection and malignant transformation and help mount an adaptive immune response. To perform such complicated tasks, NK cells express a wide set of inhibitory and activating receptors that alert them against cellular stress without damaging healthy cells. A new family of receptors that recognize nectin and nectin-like molecules has recently emerged as a critical regulator of NK cell functions. The most famous member of this family, DNAX accessory molecule (DNAM-1, CD226), is an adhesion molecule that control NK cell cytotoxicity and interferon-γ production against a wide range of cancer and infected cells. Its ligands CD112 and CD155 have been described in different pathological conditions, and recent evidence indicates that their expression is regulated by cellular stress. Additional receptors have been shown to bind DNAM-1 ligands and modulate NK cell functions bringing another level of complexity. These include CD96 (TACTILE) and TIGIT (WUCAM, VSTM3). Here, we review the role of DNAM-1, TIGIT and CD96 in NK cell biology summarizing the recent advances made on the role of these receptors in various pathologies, such as cancer, viral infections and autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24343663     DOI: 10.1038/icb.2013.95

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  53 in total

1.  Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226.

Authors:  Christopher A Fuhrman; Wen-I Yeh; Howard R Seay; Priya Saikumar Lakshmi; Gaurav Chopra; Lin Zhang; Daniel J Perry; Stephanie A McClymont; Mahesh Yadav; Maria-Cecilia Lopez; Henry V Baker; Ying Zhang; Yizheng Li; Maryann Whitley; David von Schack; Mark A Atkinson; Jeffrey A Bluestone; Todd M Brusko
Journal:  J Immunol       Date:  2015-05-20       Impact factor: 5.422

Review 2.  Clinical utility of natural killer cells in cancer therapy and transplantation.

Authors:  David A Knorr; Veronika Bachanova; Michael R Verneris; Jeffrey S Miller
Journal:  Semin Immunol       Date:  2014-03-05       Impact factor: 11.130

3.  Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation.

Authors:  Catharina C Gross; Andreas Schulte-Mecklenbeck; Anna Rünzi; Tanja Kuhlmann; Anita Posevitz-Fejfár; Nicholas Schwab; Tilman Schneider-Hohendorf; Sebastian Herich; Kathrin Held; Matea Konjević; Marvin Hartwig; Klaus Dornmair; Reinhard Hohlfeld; Tjalf Ziemssen; Luisa Klotz; Sven G Meuth; Heinz Wiendl
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-09       Impact factor: 11.205

Review 4.  Balancing natural killer cell activation through paired receptors.

Authors:  Ludovic Martinet; Mark J Smyth
Journal:  Nat Rev Immunol       Date:  2015-03-06       Impact factor: 53.106

5.  Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

Authors:  Camille Guillerey; Lucas Ferrari de Andrade; Slavica Vuckovic; Kim Miles; Shin Foong Ngiow; Michelle C R Yong; Michele W L Teng; Marco Colonna; David S Ritchie; Marta Chesi; Martha Chesi; P Leif Bergsagel; Geoffrey R Hill; Mark J Smyth; Ludovic Martinet
Journal:  J Clin Invest       Date:  2015-04-20       Impact factor: 14.808

Review 6.  Poliovirus Receptor: More than a simple viral receptor.

Authors:  Jonathan R Bowers; James M Readler; Priyanka Sharma; Katherine J D A Excoffon
Journal:  Virus Res       Date:  2017-09-08       Impact factor: 3.303

Review 7.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

8.  IL12-mediated sensitizing of T-cell receptor-dependent and -independent tumor cell killing.

Authors:  Matthias Braun; Marie L Ress; Young-Eun Yoo; Claus J Scholz; Matthias Eyrich; Paul G Schlegel; Matthias Wölfl
Journal:  Oncoimmunology       Date:  2016-05-19       Impact factor: 8.110

9.  Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing.

Authors:  Conor J Kearney; Kelly M Ramsbottom; Ilia Voskoboinik; Phillip K Darcy; Jane Oliaro
Journal:  Oncoimmunology       Date:  2016-06-27       Impact factor: 8.110

Review 10.  Combination cancer immunotherapy and new immunomodulatory targets.

Authors:  Kathleen M Mahoney; Paul D Rennert; Gordon J Freeman
Journal:  Nat Rev Drug Discov       Date:  2015-08       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.